Patent: 8,603,480
Summary for Patent: 8,603,480
| Title: | Human cytomegalovirus neutralizing antibodies and use thereof |
| Abstract: | The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. |
| Inventor(s): | Antonio Lanzavecchia, Annalisa Macagno |
| Assignee: | Institute for Research in Biomedicine IRB |
| Application Number: | US13/003,603 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,603,480
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | SYLVANT | siltuximab | For Injection | 125496 | April 23, 2014 | ⤷ Start Trial | 2029-07-15 |
| Eusa Pharma (uk) Limited | SYLVANT | siltuximab | For Injection | 125496 | April 23, 2014 | ⤷ Start Trial | 2029-07-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,603,480
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2009272284 | ⤷ Start Trial |
| Brazil | PI0916443 | ⤷ Start Trial |
| Canada | 2730776 | ⤷ Start Trial |
| Canada | 3022196 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
